ABT heads into Q2 earnings results with growth expected across Diagnostics, Devices and EPD, while Nutrition remains a drag. Here's what could shape the results.

zacks.com - 2026-07-14 10:35:14

Abbott Laboratories (NYSE: ABT | ABT Price Prediction) and Pfizer (NYSE: PFE) both delivered Q1 2026 beats, yet the market treats them differently.

247wallst.com - 2026-07-13 16:47:09

Beyond analysts' top-and-bottom-line estimates for Abbott (ABT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

zacks.com - 2026-07-13 10:15:22

Abbott Laboratories (NYSE:ABT | ABT Price Prediction) and Danaher (NYSE:DHR) both closed the books on Q1 2026 with very different stories.

247wallst.com - 2026-07-10 14:18:48

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

zacks.com - 2026-07-09 10:31:08

Abbott Laboratories offers a highly diversified healthcare portfolio with strong profitability across diagnostics and medical devices. Glaukos provides high-growth potential through its specialized focus on disruptive ophthalmic technologies for glaucoma and corneal care.

fool.com - 2026-07-08 17:03:46

Becton, Dickinson supplies equipment whose demand is soaring due to the rise of GLP-1 medicines. Abbott Laboratories' most important growth driver could benefit from greater adoption of GLP-1 drugs.

fool.com - 2026-07-07 17:30:00

Investors can count on these stocks about as much as any to continue their decades-long runs of excellence.

fool.com - 2026-07-07 14:00:00

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

zacks.com - 2026-07-06 10:01:12

These three healthcare stocks provide stability, relatively high dividend yields, and consistent growth.

fool.com - 2026-07-06 08:30:00

Abbott Laboratories is upgraded to Buy ahead of Q2 2026 earnings, following a challenging period marked by share price underperformance. The recent acquisition of Exact Sciences adds a high-growth cancer diagnostics vertical, targeting $3bn incremental 2026 sales and potential long-term revenue expansion. 2026 guidance projects 6.5–7.5% organic sales growth and $5.38–$5.58 adjusted EPS, with Exact Sciences acquisition causing $0.20 EPS dilution.

seekingalpha.com - 2026-07-03 16:00:00

Passive income is characterized by its ability to generate revenue without requiring the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence.

247wallst.com - 2026-07-02 08:18:39

Abbott Laboratories offers a highly diversified revenue stream across medical devices, diagnostics, nutrition, and generic medicines. Intuitive Surgical maintains a dominant position in robotic-assisted surgery with a high-margin, recurring revenue business model.

fool.com - 2026-07-01 16:08:55

Futures are trading lower as we get ready to start the third quarter after a record-setting second quarter that saw the Dow Jones Industrial Average close at 52,317, up 0.26% to finish the venerable index's best first half since 2021, while the Nasdaq finished the session at 26,213, up 1.52% for the tech-heavy index's best quarterly finish since 2020.

247wallst.com - 2026-07-01 08:03:14

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

benzinga.com - 2026-07-01 07:02:14

The latest trading day saw Abbott (ABT) settling at $92.71, representing a -1.5% change from its previous close.

zacks.com - 2026-06-29 18:51:14

This relationship between inflation and value stocks' outperformance is often overlooked. Many investment experts mistakenly believe that a strong economy, not inflation, is the key to value stocks beating growth stocks.

marketwatch.com - 2026-06-29 16:43:00

AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.

fool.com - 2026-06-29 11:43:02

ABT's Medical Devices unit builds on strong growth with new diabetes, heart rhythm and electrophysiology advances ahead of Q2 2026.

zacks.com - 2026-06-29 10:21:14

The U.S. Justice ​Department closed a ‌criminal probe into Abbott ​Laboratories over ​how it managed a ⁠baby ​formula facility where ​potentially deadly bacteria were discovered and ​suspected ​of causing infant deaths, ‌and ⁠instead opted for civil penalties, the ​Wall ​Street ⁠Journal reported on ​Sunday, citing ​people ⁠familiar with the matter.

reuters.com - 2026-06-28 21:17:13

WASHINGTON—The Justice Department spent years investigating Abbott Laboratories ABT 0.94%increase; up pointing triangle over how it managed a baby formula facility where potentially deadly bacteria was discovered and suspected of causing infant deaths, worsening a national shortage.

wsj.com - 2026-06-28 21:00:00

During times of market turmoil, investors cycle back into defensive, dividend-focused names like Abbott Laboratories. Besides Dividend King status and a moderately high dividend yield, this diversified healthcare stock also trades at a discount to peers like Johnson & Johnson.

fool.com - 2026-06-28 10:05:00

DXCM outpaces Abbott with expanding CGM access, new product launches and broader coverage, making it the stronger stock to watch now.

zacks.com - 2026-06-26 09:36:09

Abbott Laboratories (NYSE:ABT | ABT Price Prediction) at $90.53 is a Buy.

247wallst.com - 2026-06-25 14:20:27

ABBOTT PARK, Ill., June 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2026 financial results on Thursday, July 16, before the market opens.

prnewswire.com - 2026-06-25 09:00:00

Abbott Laboratories (NYSE:ABT | ABT Price Prediction) is a stock with characteristics suited to multi-decade ownership, because its four-segment healthcare engine, 54 consecutive years of dividend increases, and recession-resistant end markets give a retirement-focused portfolio something rare: cash compounding that does not require monitoring.

247wallst.com - 2026-06-24 13:36:42

MMED expands its European diabetes tech reach with Abbott sensor integration, boosting user flexibility and its connected care ecosystem.

zacks.com - 2026-06-24 13:21:16

ABT's Emerging Markets drive EPD growth, with strong branded generics demand, biosimilar expansion and new approvals boosting momentum.

zacks.com - 2026-06-24 09:56:02

ALZpath Strengthens Market Leadership with Abbott Agreement to Help Enable Early Alzheimer's Diagnosis at Global Scale CARLSBAD, Calif., June 24, 2026 /PRNewswire/ -- ALZpath Inc.,  the leader in blood test-based diagnostic solutions for Alzheimer's disease, today announced a licensing agreement with Abbott (NYSE: ABT), a global healthcare leader, to incorporate ALZpath's proprietary phosphorylated Tau 217 (pTau217) antibody into the development of an in vitro diagnostic (IVD) test for Alzheimer's disease.

prnewswire.com - 2026-06-24 08:30:00

ALZpath said on Wednesday it had signed a global licensing agreement with Abbott Laboratories to help advance blood-based ​testing for Alzheimer's disease, as companies race to offer ‌easier-to-use diagnostic options for the brain-wasting disease.

reuters.com - 2026-06-24 07:36:33

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

zacks.com - 2026-06-23 10:01:18

These players sell market-leading products and are tackling growth industries. Holding for several years, rather than a short period, allows investors to fully benefit from each company's story.

fool.com - 2026-06-23 06:05:00

Despite optimism about parenthood, unrealistic online portrayals are adding pressure for today's young parents Through the new "Love Without Measure" initiative, Similac is standing with parents in promoting more authentic portrayals of parenthood and pushing back on comparison culture ABBOTT PARK, Ill., June 22, 2026 /PRNewswire/ -- Parenthood is widely anticipated as one of life's most fulfilling journeys, yet for today's new parents – especially Gen Z – that excitement is often met with feelings of pressure and judgment and amplified by picture-perfect social media portrayals.

prnewswire.com - 2026-06-22 12:00:00

ABT falls 29.4% YTD as respiratory testing weakness, China uncertainty and acquisition dilution pressure results and outlook.

zacks.com - 2026-06-22 10:11:14

Long-term growth matters more than a single quarter. Abbott benefits from multiple healthcare growth trends.

fool.com - 2026-06-20 15:15:00

TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.

barrons.com - 2026-06-18 14:14:00

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

forbes.com - 2026-06-17 12:30:08

ABT's CGM sales growth slows in Q1, but management sees a return to double-digit gains as Libre expands with new products and AI tools.

zacks.com - 2026-06-16 10:51:24

Wall Street rallied toward record highs Monday as President Donald Trump declared the Strait of Hormuz reopened and oil prices plunged, yet a cluster of the market's biggest names are still trading well below their pre-war levels.

benzinga.com - 2026-06-15 11:29:34

Now's the time to load up on these high-yielders.

fool.com - 2026-06-15 04:44:00

Abbott (ABT) closed the most recent trading day at $88.18, moving 1.64% from the previous trading session.

zacks.com - 2026-06-12 18:50:27

Abbott declares 410th consecutive quarterly dividend PR Newswire ABBOTT PARK, Ill., June 12, 2026

gurufocus.com - 2026-06-12 15:00:00

ABBOTT PARK, Ill., June 12, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.

prnewswire.com - 2026-06-12 14:29:00

Abbott Laboratories is rated a strong buy due to structural undervaluation and resilient fundamentals despite recent negative price action. ABT trades at a 17.1% P/E and 35.1% sales multiple discount to peers, with DCF fair value estimates implying 21.8–39.4% upside. Growth is underpinned by the Exact Sciences acquisition, diagnostics megatrends, and global expansion in CGM, with FY26 guidance raised for both sales and EPS.

seekingalpha.com - 2026-06-12 03:46:33

In the most recent trading session, Abbott (ABT) closed at $89.17, indicating a -2.28% shift from the previous trading day.

zacks.com - 2026-06-10 19:02:01

ABT's Exact Sciences acquisition expands its cancer diagnostics portfolio as new data and screening guidelines strengthen growth prospects.

zacks.com - 2026-06-10 10:26:08

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

zacks.com - 2026-06-10 10:01:27

The stocks listed here have excellent financials and possess terrific growth opportunities. They also pay dividends, which can help boost your returns.

fool.com - 2026-06-09 17:00:00

Study at ADA's Scientific Sessions shows participants in Abbott's Healthy Food Rx program combined with health coaching had significant health improvements Abbott's Healthy Food Rx program is a Food is Medicine initiative delivering recipe-based food boxes and nutrition education to people living with diabetes NEW ORLEANS, June 8, 2026 /PRNewswire/ -- New research presented at the American Diabetes Association's 86th Scientific Sessions showed that adults living with type 2 diabetes participating in Abbott's (NYSE: ABT) Healthy Food Rx "Food is Medicine" program, paired with community health worker–led coaching, experienced major improvements in healthy eating, physical activity, diabetes self-management, food insecurity and self-reported physical and mental health. Conducted with the Public Health Institute Center for Wellness and Nutrition (PHI CWN), the Asian Pacific Self-Development and Residential Association (APSARA) and the Emergency Food Bank of Stockton/San Joaquin (EFB), and with funding from Abbott's philanthropic foundation Abbott Fund, the study assessed 284 participants living with type 2 diabetes who received Healthy Food Rx food boxes alongside community health worker–led coaching over a six-month period.

prnewswire.com - 2026-06-08 09:00:00

In the first quarter of 2026, Baron Discovery Fund declined 10.65% (Institutional Shares), trailing the Russell 2000 Growth Index by 7.84% due to significant underperformance in the software sector. Advanced Energy Industries, Inc.'s stock rose during the quarter as the market began to appreciate the strength that the company would see in both its data center and semiconductor end markets. Baron Discovery Fund sold its investment in Intapp, Inc. in the quarter as the team believes that its other software holdings have better overall competitive advantages.

seekingalpha.com - 2026-06-08 01:35:00